Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer

Clelia Madeddu a, Giulia Gramignano b, Carlo Floris c, Giuseppe Muren u d, Giuseppe Sollai e, Antonio Macci o, f, *

a Department of Medical Sciences “Mario Aresu”, University of Cagliari, Cagliari, Italy
b Medical Oncology Unit, San Gavino Hospital, San Gavino, Italy
c Department of Medical Oncology, Nuova Casa di Cura, Cagliari, Italy
d Department of Experimental Surgery, “A. Businco” Oncological Hospital, Cagliari, Italy
e Department of Oncological Surgery, “A. Businco” Oncological Hospital, Cagliari, Italy
f Department of Gynecologic Oncology, “A. Businco” Oncological Hospital, Cagliari, Italy

Received: April 7, 2014; Accepted: July 30, 2014

Abstract

Weight gain and obesity are among the most important risk factors for post-menopausal oestrogen-dependent breast cancer (EDBC). Weight gain is associated with oxidative stress, which in turn promotes breast cancer progression. We carried out a prospective study in 216 consecutive post-menopausal breast cancer patients aiming to examine the correlations between traditional prognostic factors (tumour size, T, nodal, N, grading, G, and metastasis status, M), and body mass index (BMI), leptin, pro-inflammatory cytokines (Interleukin, IL-6 and tumour necrosis factor-alpha, TNF-α), and oxidative stress (reactive oxygen species, ROS, glutathione peroxidase, GPx, superoxide dismutase, SOD) among patients with oestrogen receptor (ER)+ and ER− breast cancers. Distribution of T, N and M categories did not differ between ER+ and ER− breast cancer patients. ER− patients showed a higher incidence of G3 tumours. Weight, BMI, leptin, IL-6 and ROS were higher in ER+ compared with ER− patients. Among ER+ patients, BMI, leptin, IL-6 and ROS correlated with T and M. Leptin, IL-6 and ROS were positively correlated also with N. Among ER− patients, BMI and leptin did not correlate with any of prognostic parameters, whereas a positive correlation between IL-6, ROS and M was found. Multivariate regression analysis showed that BMI, leptin, IL-6 and ROS were predictive for T, N and M in ER+ patients. Weight gain, inflammation and oxidative stress are involved in EDBC prognosis. Their modulation through antidiabetic, anti-inflammatory and antioxidants drugs combined with endocrine therapy may constitute a targeted approach in post-menopausal EDBC.

Keywords: oestrogen-dependent breast cancer ● leptin ● adiposity ● Interleukin-6 ● oxidative stress

Introduction

Weight gain and obesity are among the most important factors that predict risk for oestrogen-dependent breast cancer (EDBC) in post-menopausal women [1]. Several pieces of evidence explain this association. (i) The levels of circulating oestrogens derived from peripheral aromatization of androgens are higher in overweight women than in slim post-menopausal women. (ii) Adiposity results in higher circulating levels of insulin and insulin-like growth factor (IGF), which stimulate growth of epithelial breast cells and induce neoplastic transformation. (iii) Obesity is associated with lower levels of sex-hormone binding globulin (SHBG), which correlate with increased bioavailability of circulating oestrogens [2].

More recently, it has been shown that adipose tissue is an active endocrine-immune organ that secretes adipokines [3], inflammatory cytokines and polypeptides that promote EDBC [4]. The plasma concentrations of leptin, tumour necrosis factor (TNF)-α and interleukin-6 (IL-6) positively correlate with body mass index (BMI) in overweight and obese women [4]. The increased levels of leptin and pro-inflammatory cytokines are directly associated with breast cancer development [5]. As a result of inflammatory and metabolic changes, weight gain is also associated with oxidative stress [6]. Oxidative stress damages lipids, proteins and nucleic acids [7, 8], and induces activation of
Akt/PI3K/mTOR signalling, promoting oncogenesis, and tumour progression, in EDBC [9, 10]. The aim of this prospective observational study was to examine in a population of post-menopausal breast cancer patients the correlations between traditional prognostic factors, and BMI, leptin, circulating levels of pro-inflammatory cytokines (IL-6, TNF-α), and oxidative stress (reactive oxygen species, ROS, glutathione peroxidase, GPx, superoxide dismutase, SOD). Correlations were examined among patients with oestrogen receptor (ER)+ and among patients with ER− breast cancers. Traditional prognostic factors included grade (G), tumour size (T), node (N) and metastases (M) status according to tumour prognostic categories (TNM) staging.

Patients and methods
Two hundred and sixteen consecutive breast cancer patients referred to the Medical Oncology Units at the ‘N.S. Bonaria’ Hospital in San Gavino, at the ‘Nuova Casa di Cura’ in Decimomannu and at the ‘A Businco’ Hospital, Cagliari, Italy, were enrolled in the study between June 2009 and September 2013. Eligible patients were post-menopausal and had a histologically confirmed diagnosis of breast cancer. ER positivity was assigned if more than 1% of tumour cells stained positive for the oestrogen receptor. Exclusion criteria were a prior malignancy, active use of exogenous hormones (hormone-replacement therapy) at the time of enrolment, and among patients with oestrogen receptor (ER)+ and among patients with ER− breast cancers. Traditional prognostic factors included grade (G), tumour size (T), node (N) and metastases (M) status according to tumour prognostic categories (TNM) staging.

Measurement
Tumour histology, G, T, N and ER status were obtained from pathology reports. Tumour, N and M status were staged according to the TNM staging system. Hormone receptors were assessed by immunohistochemical assays on a selected tumour block after formal surgical excision. ER was considered positive if there was >1% nuclear staining, as stated in the most recent guidelines from the American Society of Clinical Oncology and the College of American Pathologists for immunohistochemical analysis of ER in breast cancer [11]. Baseline anthropometric measurements and blood collection were performed at the time of surgery and before any systemic treatment. Weight was measured with a balance-beam scale after a 12-hr overnight fast with patients clothed in a hospital gown. BMI was calculated as weight (kg)/height (m²). Fasting blood (10 ml) was collected in the morning (between 8 and 9 a.m.) and placed in heparinized tubes. Samples were immediately centrifuged, and serum was stored at −70°C without thawing before performing the leptin and pro-inflammatory cytokine assays. Oxidative stress parameters were measured in fresh blood samples.

Assessment of serum leptin and pro-inflammatory cytokine levels
Serum leptin levels were measured by a double-antibody ‘sandwich’ ELISA test (DRG Instruments, Marburg, Germany). The absorbance was measured at 450 ± 10 nm. The intra-assay and interassay variations were 5% and 7% respectively. The results were expressed in nanograms per millilitre (ng/ml). Pro-inflammatory cytokines IL-6 and TNF-α were detected in duplicate by a ‘sandwich’ ELISA with commercially available kits (DRG Instruments GmbH, Marburg, Germany). The absorbance was measured at 450 nm with a spectrophotometer. Intra-assay variations were 3% for IL-6 and 6% for TNF-α. Interassay coefficients of variation were less than 5% for both cytokines. The results were expressed in picograms per millilitre (pg/ml).

Assessment of blood levels of ROS and antioxidant enzymes GPx and SOD
Blood levels of ROS were determined with the FORT test (Callegari, Parma, Italy). Results were expressed as FORT U (1 FORT U corresponds to 0.26 mg/l H2O2). Erythrocyte GPx and SOD activities were measured with a commercially available kit (Ransod; Random Lab, Crumlin, UK). Results were expressed in U/L for GPx and U/mL for SOD.

Statistical analysis
Considering a probability of 99% to detect a relationship between the independent and dependent variables at a two-sided significance level of 0.01 and a change in the dependent variables of 5 units per unit change of the independent variable (with a standard deviation of 10 and 1 respectively), a sample size of at least 200 patients should be enrolled. Descriptive means and standard deviations were generated for all study variables. The distribution of the continuous variables was checked for linearity. Differences in the anthropometrics, clinical characteristics and laboratory parameters of ER− compared to ER+ cancer patients were tested by the Student’s t-test for continuous variables or the chi-squared test for categorical variables.

After checking the linearity of the data distribution and the variability among the ER− and ER+ groups, the differences in the mean levels of BMI, leptin, pro-inflammatory cytokines (IL-6 and TNF−α) and oxidative stress parameters (ROS, GPx and SOD) were compared across categories of tumour prognostic factors (pT, pN, G and M status) by one-way ANOVA. Spearman rank correlation coefficients were calculated to examine cross-sectional interrelationships between adiposity (BMI and leptin), pro-inflammatory cytokines (IL-6 and TNF−α) and oxidative stress parameters (ROS, GPx and SOD). Then, correlations between BMI, leptin, pro-inflammatory cytokines and oxidative stress parameters and tumour prognostic factors (T, N, G and M status) were tested by Spearman’s correlation test. Significant correlations were tested by multivariate regression analyses to evaluate the predictive roles of BMI, leptin, pro-inflammatory cytokines (IL-6 and TNF−α) and oxidative stress parameters (ROS, GPx and SOD) versus tumour prognostic characteristics. Results were considered significant for P < 0.01. All p values are two-tailed. Statistical analyses were performed with SPSS, version 15.0 (SPSS Inc., Chicago, IL, USA).

Results
Two hundred and sixteen consecutive post-menopausal breast cancer patients were enrolled: 151 were ER+ and 65 were ER−. The baseline clinical characteristics of the patients are reported in Table 1. Patient distributions across tumour categories (T, N, M) did not significantly
differ between ER+ and ER− breast cancer patients. Notably, G distribution and Ki-67 mean expression were significantly different between ER+ and ER−: in fact, ER− showed a higher incidence of G3 tumours and a mean higher value of Ki-67 expression. The percentage of patients with type 2 diabetes at diagnosis was higher for ER+ patients compared to that in ER−.

Evaluation of BMI, leptin, pro-inflammatory cytokines and oxidative stress parameters according to ER status in post-menopausal breast cancer patients

ER+ patients showed significantly higher BMI and leptin levels in comparison with that of ER− breast cancer patients. As for pro-inflammatory cytokines, IL-6 was significantly higher in ER+, whereas TNF-α was not significantly different in the two groups of patients studied (Table 2 and Fig. 1). The levels of ROS were significantly higher in ER+ patients in comparison to those in ER− breast cancer patients. GPx and SOD were not significantly different between the two patient groups (Table 2 and Fig. 2).

Evaluation of BMI, leptin, pro-inflammatory cytokines and oxidative stress parameters across TNM within ER+ and ER− breast cancer patients

Among ER+ patients, BMI and serum leptin levels were significantly higher in those patients with higher values for T, N and M+ status. Among ER− patients, no differences in BMI or serum leptin levels were observed across the different prognostic categories (Table 3). Among ER+ patients relatively pro-inflammatory cytokines only the IL-6 was significantly higher in those who had a higher tumour size, nodal involvement (N+) and distant metastases (M+). No
Table 2 Baseline values of BMI, leptin, pro-inflammatory cytokines and oxidative stress parameters in post-menopausal breast cancer patients according to ER status

| Parameters                  | ER+ breast cancer patients | ER− breast cancer patients | P-value |
|-----------------------------|---------------------------|---------------------------|---------|
| BMI, kg/m² (mean ± SD)      | 26.7 ± 4.6                | 24.6 ± 3.9                | 0.035   |
| BMI categories              |                           |                           |         |
| <18.5                       | 2                         | 4                         |         |
| 18.5-24.9                   | 49                        | 58                        |         |
| 25-29.9                     | 26                        | 27                        |         |
| >30                         | 21                        | 6                         |         |
| Leptin, ng/ml (mean ± SD)   | 53.1 ± 38                  | 24.2 ± 14.2               | <0.001  |
| IL-6, pg/ml (mean ± SD)     | 28.2 ± 20.4               | 16.5 ± 10.6               | <0.001  |
| TNF-α, ng/ml (mean ± SD)    | 19.4 ± 10.7               | 16.2 ± 14.4               | 0.115   |
| ROS, FORT U (mean ± SD)     | 385 ± 74                  | 325 ± 58                  | 0.002   |
| GPx, U/ml (mean ± SD)       | 8396 ± 2750               | 7542 ± 1461               | 0.120   |
| SOD, U/l (mean ± SD)        | 110 ± 39                  | 91 ± 57                   | 0.067   |

ER, oestrogen receptor; BMI, body mass index; IL, interleukin; TNF, tumour necrosis factor; ROS, Reactive oxygen species; GPx, glutathione peroxidase; SOD, superoxide dismutase.

Fig. 1 Serum levels of IL-6, TNF-α and leptin in post-menopausal breast cancer patients according to ER status. Patients with ER+ breast cancer showed significantly higher levels of IL-6 and leptin in comparison with ER− breast cancer patients. The box plots in the figure represent columns of data as boxes whose extents indicate the 25th and 75th percentiles of the column. The line inside the box represents the median. + marks the value of the mean. Capped bars indicate the minimum and maximum value observed. IL, Interleukin; TNF, Tumour necrosis Factor; ER, oestrogen receptor.

Fig. 2 Blood levels of oxidative stress parameters (ROS, GPx and SOD) in post-menopausal breast cancer patients according to ER status. Patients with ER+ breast cancer showed significantly higher levels of ROS in comparison with ER− breast cancer patients. The box plots in the figure represent columns of data as boxes whose extents indicate the 25th and 75th percentiles of the column. The line inside the box represents the median. + marks the value of the mean. Capped bars indicate the minimum and maximum value observed. ROS, reactive oxygen species; GPx, glutathione peroxidase; SOD, superoxide dismutase; ER, oestrogen receptor.
### Table 3 Evaluation of BMI, leptin and pro-inflammatory cytokines across tumour categories among ER+ and ER− post-menopausal breast cancer patients

| Tumour characteristics | ER+ breast cancer patients | ER− breast cancer patients |
|------------------------|---------------------------|---------------------------|
|                        | BMI (kg/m²) | Leptin (ng/ml) | IL-6 (pg/ml) | TNF-α (pg/ml) | BMI (kg/m²) | Leptin (ng/ml) | IL-6 (pg/ml) | TNF-α (pg/ml) |
| Tumour size (T)        |             |               |              |             |             |               |              |              |
| T1                     | 23.1 ± 5.7  | 13.9 ± 4.6    | 6.7 ± 1.8    | 17.5 ± 2.3  | 24.1 ± 2.6  | 16.1 ± 5.7    | 6.7 ± 2.6    | 21.8 ± 15    |
| T2                     | 23.8 ± 2.3  | 33.9 ± 17.3   | 9.2 ± 3      | 21.7 ± 11.6 | 23.9 ± 4.1  | 21.5 ± 4.1    | 18.1 ± 11.9  | 19.8 ± 6.7   |
| T3                     | 24.9 ± 4    | 39.6 ± 50     | 20.2 ± 5.2   | 17 ± 11.2   | 25.1 ± 5.4  | 23 ± 19.7     | 23 ± 19.7    | 21.7 ± 10.7  |
| T4                     | **26.5 ± 5.2** | **47.8 ± 31.7** | **23.9 ± 7.9** | 21 ± 17.8 | 23.7 ± 6.9  | 24.6 ± 12.8   | 18.8 ± 12.8  | 27.2 ± 6.8   |
| Tumour grade (G)       |             |               |              |             |             |               |              |              |
| G1                     | 24.4 ± 4.1  | 29.9 ± 19.7   | 22 ± 10      | 20.1 ± 11.5 | 21.7 ± 4.7  | 16.7 ± 15     | 19.7 ± 5     | 17.9 ± 7.6   |
| G2                     | 23.5 ± 2.7  | 21.5 ± 18.4   | 16 ± 14      | 15.5 ± 3.2  | 22.4 ± 5.6  | 21.7 ± 12.1   | 13.8 ± 8.8   | 11.4 ± 8.8   |
| G3                     | 27.7 ± 3.5  | 37.3 ± 26.9   | 36 ± 16      | 22.7 ± 15.3 | 21.8 ± 5.8  | 17 ± 13.8     | 17 ± 4.6     | 11.9 ± 4.6   |
| Nodal status (N)       |             |               |              |             |             |               |              |              |
| N0                     | 24.1 ± 3.2  | 21 ± 16.6     | 7 ± 3.2      | 19 ± 7.8    | 22.9 ± 3    | 17.4 ± 5.0    | 7.9 ± 3.7    | 19.4 ± 12    |
| N1                     | 23.6 ± 4.5  | 35 ± 25.9     | 29.6 ± 17.8  | 16 ± 10.3   | 23.8 ± 5.7  | 24.6 ± 17.5   | 19.3 ± 13    | 18 ± 11.8    |
| N2                     | 25.5 ± 3.6  | 44.6 ± 33     | 35.9 ± 19.6  | 20.9 ± 13.2 | 24.9 ± 5.7  | 21 ± 7.3      | 23 ± 15      | 23 ± 13      |
| N3                     | **27.8 ± 4.3** | **50 ± 22.3** | **34.4 ± 21** | 28.1 ± 19.2 | 25.3 ± 4.2  | 18 ± 10.4     | 16 ± 4.1     | 21 ± 9.5     |
| Metastases status (M)  |             |               |              |             |             |               |              |              |
| M−                     | 23.1 ± 3.1  | 17.4 ± 9      | 11.8 ± 9.5   | 18 ± 4.2    | 23.7 ± 3.7  | 21.3 ± 6.1    | 10.2 ± 3.4   | 19 ± 2.6     |
| M+                     | **28 ± 3.4** | **64.7 ± 26.7** | **49.3 ± 12** | 25.3 ± 11   | 24.3 ± 4.7  | 24 ± 20       | **19 ± 13**  | 23 ± 11      |

* P < 0.05 as calculated by ANOVA test.

BMI, body mass index; IL, interleukin; TNF, tumour necrosis factor.
significant differences of IL-6 serum levels were observed in ER+ patients as for the prognostic categories T and N; vice versa, IL-6 levels were significantly higher only in M+ patients in comparison with those patients who showed no evidence of distant metastases (Table 3).

Among ER+ patients, ROS levels were significantly higher in patients with higher T, N and M+ status (Table 4). Notably, among ER+ patients, ROS levels were significantly higher only in patients with distant metastases (M+) in comparison with those patients who showed no evidence of distant metastases. Among both ER+ and ER− patients, GPx and SOD levels were not significantly different according to the T, N and M status (Table 4).

Cross-sectional interrelationships between BMI, leptin, pro-inflammatory cytokines and oxidative stress parameters

A significant positive relationship was found between leptin and BMI in ER+ breast cancer patients. BMI and leptin correlated with IL-6 levels in ER+ breast cancer patients. However, no correlations were observed for BMI, leptin and pro-inflammatory cytokine levels among ER− breast cancer patients (Table 5).

Reactive oxygen species levels were positively correlated with BMI, leptin and IL-6 in ER+ breast cancer patients. In addition, GPx, SOD and IL-6 negatively correlated in ER+ patients. In ER− patients, no significant correlations were found among oxidative stress parameters, BMI and leptin, whereas a positive correlation was found between ROS and IL-6 (Table 5).

Table 4 Evaluation of oxidative stress parameters across tumour characteristic categories among ER+ and ER− post-menopausal breast cancer patients

| Tumour size (T) | ER+ breast cancer patients | ER− breast cancer patients |
|-----------------|---------------------------|----------------------------|
|                 | ROS (FORT U) | GPx (U/L) | SOD (U/ml) | ROS (FORT U) | GPx (U/L) | SOD (U/ml) |
| T1              | 327 ± 29    | 9241 ± 435 | 101 ± 9.1  | 265 ± 44    | 9550 ± 457 | 98 ± 20.3 |
| T2              | 396 ± 32    | 9454 ± 1954| 102 ± 23   | 337 ± 62    | 8942 ± 2345| 90.6 ± 27 |
| T3              | 405 ± 44    | 8416 ± 2196| 112 ± 36   | 327 ± 105   | 8084 ± 2320| 86.9 ± 18 |
| T4              | 428 ± 99*   | 8735 ± 920 | 104 ± 29   | 344 ± 29    | 8139 ± 1494| 95 ± 13   |

| Tumour grade (G) | ER+ breast cancer patients | ER− breast cancer patients |
|------------------|---------------------------|----------------------------|
| G1               | 386 ± 74               | 8879 ± 1628                | 100 ± 22     | 296 ± 58   | 9015 ± 2353 | 96.6 ± 16.7 |
| G2               | 368 ± 87               | 8839 ± 727                 | 109 ± 24     | 345 ± 60   | 8147 ± 1567 | 91.2 ± 15.6 |
| G3               | 410 ± 41               | 9747 ± 1408                | 115 ± 30     | 339 ± 48   | 8661 ± 1994 | 94 ± 14.1  |

| Nodal status (N) | ER+ breast cancer patients | ER− breast cancer patients |
|------------------|---------------------------|----------------------------|
| N0               | 331 ± 43             | 9173 ± 445                | 102 ± 16     | 285 ± 45   | 9426 ± 1855 | 91.7 ± 18  |
| N1               | 389 ± 27             | 9326 ± 1789               | 108 ± 35     | 337 ± 54   | 9225 ± 389  | 93 ± 24    |
| N2               | 414 ± 139            | 8859 ± 22179              | 96 ± 17.6    | 318 ± 76   | 8396 ± 2751 | 90.1 ± 39  |
| N3               | 429 ± 89*            | 7739 ± 1859               | 124 ± 44     | 380 ± 58   | 8700 ± 2042 | 89 ± 35    |

| Metastases status (M) | ER+ breast cancer patients | ER− breast cancer patients |
|-----------------------|---------------------------|----------------------------|
| M−                    | 351 ± 38         | 9318 ± 1208                | 108 ± 26     | 302 ± 21   | 9483 ± 165  | 95 ± 43    |
| M+                    | 460 ± 80*        | 8463 ± 2121               | 94 ± 20      | 450 ± 51*  | 8253 ± 3155 | 90 ± 17    |

*P < 0.05 as calculated by ANOVA test.
ROS, reactive oxygen species; GPx, glutathione peroxidase; SOD, superoxide dismutase.
### Table 5 Cross-sectional interrelationships between BMI, leptin, pro-inflammatory cytokines and oxidative stress parameters

| BMI | Leptin (ng/ml) | IL-6 (pg/ml) | TNF-α (pg/ml) | ROS (FORT U) | GPx (UI/l) |
|-----|----------------|--------------|---------------|--------------|------------|
|     | **r**          |              | **r**         |              |            |
|     | **P**          |              | **P**         |              |            |
| ER+ |                |              |               |              |            |
| BMI | 0.621          | <0.001       |               |              |            |
| Leptin | 0.502          | <0.001       | 0.787         | <0.001       |            |
| IL-6 | 0.259          | 0.059        | 0.338         | 0.087        | 0.483      | 0.001      |
| TNF-α | 0.339          | 0.017        | 0.576         | 0.001        | 0.832      | <0.001     |
| ROS | 0.076          | 0.607        | −0.045        | 0.761        | −0.522     | <0.001     |
| GPx | −0.150         | 0.551        | −0.143        | 0.220        | −0.401     | 0.099      |
| SOD | −0.150         | 0.551        | −0.143        | 0.220        | −0.401     | 0.099      |

### Table 6 Correlations of BMI, leptin and pro-inflammatory cytokines with tumour prognostic characteristics

| Tumour characteristics | BMI (kg/m²) | Leptin (ng/ml) | IL-6 (pg/ml) | TNF-α (pg/ml) |
|------------------------|-------------|----------------|--------------|---------------|
|                        | Spearman’s r | P              | Spearman’s r | P              |
|                        | Spearman’s r | P              | Spearman’s r | P              |
|                        | Spearman’s r | P              | Spearman’s r | P              |
|                        | Spearman’s r | P              | Spearman’s r | P              |
| ER+                    |              |                |              |                |
| T                      | 0.552        | **0.038**      | 0.365        | **0.026**      | 0.427        | 0.002      | 0.077      | 0.617      |
| N                      | 0.226        | 0.118          | 0.334        | **0.019**      | 0.583        | <0.001     | 0.152      | 0.320      |
| G                      | 0.189        | 0.192          | 0.183        | 0.490          | 0.140        | 0.339      | 0.017      | 0.910      |
| M                      | 0.325        | **0.023**      | 0.626        | <0.001         | 0.817        | <0.001     | 0.128      | 0.128      |
| ER−                    |              |                |              |                |
| T                      | 0.035        | 0.847          | 0.215        | 0.280          | 0.259        | 0.192      | 0.142      | 0.333      |
| N                      | 0.280        | 0.115          | 0.159        | 0.428          | 0.262        | 0.186      | 0.133      | 0.508      |
| G                      | −0.219       | 0.220          | −0.257       | 0.164          | 0.109        | 0.588      | −0.186     | 0.354      |
| M                      | 0.028        | 0.876          | 0.296        | 0.134          | 0.449        | **0.045**  | 0.135      | 0.104      |

r, correlation factor; BMI, body mass index; IL, interleukin; TNF, tumour necrosis factor; ROS, reactive oxygen species; GPx, glutathione peroxidase; SOD, superoxide dismutase.
Among ER+ patients, BMI and leptin did not correlate with any of the prognostic parameters, whereas a positive correlation between IL-6 and M status was found. In ER+ patients, a significant positive correlation between ROS levels and T, N and M status was found. In ER− patients, a significant positive correlation between ROS and the presence of distant metastases (M+) was found (Table 7).

Multivariate regression analysis showed that BMI, leptin, IL-6 and ROS were predictive for T, N and M status in ER+ patients (Table 8).

### Discussion

In post-menopausal women, excessive weight and obesity are associated with increased oestrogen levels because of the aromatase enzyme and consequent risk of EDBC [1]. Recently, it was demonstrated that an imbalance in the production of adipokines, i.e. leptin, has a role in the link between weight and EDBC [12, 13]. Furthermore, adiposity, especially in the context of obesity and metabolic syndrome, is associated with high levels of IL-6 and TNF-α. The roles of these inflammatory cytokines in oncogenesis and tumour progression of EDBC are well established [9].

In the present study, we confirmed that the highest BMI was linked to EDBC in post-menopausal patients [14]. Furthermore, leptin levels in ER+ patients were significantly higher than those in ER− patients. Among ER+ BMI and leptin significantly correlated with T, N and M status; then, BMI and leptin were predictive factors for the main prognostic parameters. Several studies link leptin levels with breast cancer risk [15–17]. Serum leptin, which is derived from adipose tissue in proportion to fat content, correlates with total body aromatase activity in post-menopausal patients [18]. Leptin affects several intracellular messengers that regulate proliferation and survival of breast cancer cells [19]. Notably, our results indicated that leptin specifically correlated with prognosis only among post-menopausal patients with ER+ breast cancer.

Furthermore, only in ER+ breast cancer patients, we also demonstrated a positive relationship of BMI, leptin, with IL-6. Interleukin-6 in turn was predictive of tumour T, N and M status only in ER+ patients. Pro-inflammatory cytokines may influence breast carcinogenesis through indirect weight-related effects, such as the development of insulin resistance [20, 21] or the modulation of aromatase activity within adipose tissue [22]. In addition, IL-6 appears to be directly involved in the activation of NF-kB/STAT-3 [23] and insulin resistance [24]. Accordingly with this evidence, in our study several of the patients with EDBC had type-2 diabetes. Insulin resistance and elevated levels of insulin and IGF are known to induce breast cancer growth. Insulin down-regulates expression of insulin-like growth factor-binding proteins within the breast, increasing the bioavailability of IGF-1 and stimulating tumour development [25]. An indirect mechanism of action of insulin on breast carcinogenesis is the increased level of bioavailable oestrogen as a result of decreased hepatic synthesis of SHBG [26]. Moreover, insulin and IGF-1 activate the breast Akt/PI3K/mTOR pathway, which promotes cell growth and proliferation [27]. In the last years the PI3K/AKT/mTOR signalling has been found to exert a central role in the regulation of breast cancer cell growth and to modulate oestrogen receptor function. This pathway is strictly linked with several other regulatory systems for glucose-, lipid- and amino-acid- metabolism, for energy balance and autophagy [28]. Interestingly, the Akt/PI3K/mTOR cascade mediates signalling from leptin and IL-6 [29], which in our have been shown to be significantly

### Table 7 Correlation between oxidative stress parameters and tumour prognostic characteristics

| Tumour characteristics | ROS (FORT U) Spearman’s r | P | GPx (U/l) Spearman’s r | P | SOD (U/ml) Spearman’s r | P |
|------------------------|----------------------------|---|------------------------|---|------------------------|---|
| **ER+**                |                            |   |                        |   |                        |   |
| T                      | 0.355                      | 0.012 | -0.180                | 0.220 | -0.092                | 0.534 |
| N                      | 0.390                      | 0.006 | -0.181                | 0.217 | 0.076                 | 0.610 |
| G                      | 0.047                      | 0.750 | 0.280                 | 0.058 | 0.248                 | 0.089 |
| M                      | 0.745                      | <0.001 | -0.187                | 0.073 | -0.241                | 0.060 |
| **ER−**                |                            |   |                        |   |                        |   |
| T                      | 0.384                      | 0.086 | -0.299                | 0.155 | -0.041                | 0.871 |
| N                      | 0.247                      | 0.082 | -0.268                | 0.205 | -0.079                | 0.620 |
| G                      | 0.328                      | 0.147 | -0.025                | 0.907 | -0.202                | 0.421 |
| M                      | 0.688                      | 0.001 | -0.121                | 0.414 | -0.073                | 0.623 |

r, correlation factor; ROS, reactive oxygen species; GPx, glutathione peroxidase; SOD, superoxide dismutase.
The bold values correspond to significant P value.

[^2526]: © 2014 The Authors.

Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
The role of oxidative stress and breast cancer prognosis may be intrinsic to an oestrogen-positive (luminal) phenotype [40]. It is likely that an association between oxidative stress and breast cancer prognosis may be intrinsic to an oestrogen-genotoxic effects, which lead to breast cancer initiation and/or progression [36]. Moreover, a pro-oxidative gene expression profile is associated with metastasis-free and overall survival in ER+ breast cancer patients, including both ER+ and ER− cancers, showed that oxidative stress parameters were positively associated with breast cancer in post-menopausal women with higher BMI. Thus, the role of oxidative stress in breast cancer development may depend on adiposity [33]. More recently, a large case-control study showed that the association between increased oxidative stress parameters were positively associated with breast cancer in post-menopausal patients.

We showed that ROS levels were significantly higher in EDBC patients and correlated with BMI, leptin, and T, N and M status. In particular, multivariate analysis showed that ROS were predictive for T, N and M status in patients with EDBC. Of note, in our study we found that also among ER− patients, ROS levels were positively correlated with IL-6, but they were both positively correlated only with M+. These findings confirm the evidence that all the metastatic diseases are characterized by the presence of chronic inflammation and associated increased ROS levels.

Consistent with our results, a central role for oxidative stress in the pathogenesis of oestrogen-induced breast cancer has been suggested. A case-control study in a wide population of breast cancer patients, including both ER+ and ER− cancers, showed that oxidative stress parameters were positively associated with breast cancer in post-menopausal women with higher BMI. Thus, the role of oxidative stress in breast cancer development may depend on adiposity [33]. More recently, a large case-control study showed that the association between increased oxidative stress and breast cancer was significant in ER+ cancers [32]. ROS are involved in oestrogen-genotoxic effects, which lead to breast cancer initiation and/or progression [36]. In vitro oestrogen exposure induces ROS production selectively in ER+ MCF7 cells [37, 38]. Moreover, a pro-oxidative gene expression profile is associated with metastasis-free and overall survival in ER+ breast tumours [40]. It is likely that an association between oxidative stress and breast cancer prognosis may be intrinsic to an oestrogen-positive (luminal) phenotype [40]. The role of oxidative stress in ER+ breast cancer has also therapeutic implications. Increased oxidative stress in ER+ tumours seems to be associated with reduced sensitivity to conventional hormonal therapies [41]. Tamoxifen resistance in ER+ MCF-7 cells is associated with oxidative stress, increased phosphorylation of JNK and c-Jun, and increased AP-1 activity [42]. Moreover, cross-talk between the ER and PI3K/Akt/mTOR signalling has been demonstrated as a mechanism of endocrine resistance [43]. Blockade of both pathways enhances antitumour activity in pre-clinical and clinical models of breast cancer.

In conclusion, weight gain, inflammation and oxidative stress are highly involved in the pathogenesis, progression and prognosis of EDBC. Then, the selective modulation of leptin, pro-inflammatory cytokines and ROS through antidiabetic [44], anti-inflammatory [45] and antioxidants drugs [46] may constitute a new targeted therapeutic approach in post-menopausal EDBC and may potentiate the efficacy of anti-aromatase treatments in this setting of patients.

### Acknowledgements

Work supported by the “Associazione Sarda per la ricerca nell’Oncologia Ginecologica-ONLUS” with a funding from “Banco di Sardegna” Foundation (grant no. 5335, 2014). The authors thank Dr Giorgia Antoni (Bsc) for her technical assistance. The authors thank the City Government of Carloforte, San Pietro Island, Sardinia, Italy, for its support.

### Conflicts of interest

The authors confirm that there are no conflicts of interest.

### Author contribution

CM, GG and AM designed the research study; CM, GG, CF, GM, GS and AM performed the research; CM contributed to the laboratory assessments; CM, GG and AM analysed the data; CM, GG, CF, GM, GS wrote the paper.
References

1. Maccio A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev. 2009; 10: 660–70.
2. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94: 606–16.
3. Dizdar O, Alyamac E. Obesity: an endocrine tumor? Med Hypotheses. 2004; 63: 790–2.
4. Vona-davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14: 199–206.
5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89: 2548–56.
6. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752–61.
7. Bermano G, Smyth E, Goua M, et al. Impaired expression of glutathione peroxidase-4 gene in peripheral blood mononuclear cells: a biomarker of increased breast cancer risk. Cancer Biomark. 2010; 7: 39–46.
8. Kedzierska M, Olas B, Wachowicz B, et al. The lipid peroxidation in breast cancer patients. Gen Physiol Biophys. 2010; 29: 208–10.
9. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010; 28: 4056–65.
10. Acharya A, Das I, Chandhok D, et al. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2010; 3: 23–34.
11. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784–95.
12. Khan S, Shukla S, Sinha S, et al. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev. 2013; 24: 503–13.
13. van Kuijdsijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569–78.
14. Maccio A, Madeddu C, Gramignano G, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med. 2010; 88: 677–86.
15. Niu J, Jiang L, Guo W, et al. The association between leptin level and breast cancer: a meta-analysis. PLoS ONE. 2013; 8: e67349.
16. Wu MH, Chou YC, Chou WY, et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100: 578–82.
17. Cust AE, Stocks T, Lukanova A, et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009; 113: 567–76.
18. Geisler J, Haynes B, Ekse D, et al. Total body fatness in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Steroid Biochem Mol Biol. 2007; 104: 27–34.
19. Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004; 64: 5870–7.
20. Ruan H, Lodish HF. Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 2003; 14: 447–55.
21. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obesity Res. 2001; 9: 414–7.
22. Purohit A, Ghilchik MW, Duncan L, et al. Arouse: context dependent interplay of SOCS3 and AMPK. J Diabetes Metab. 1995; 80: 3052–8.
23. Ghosh S, Ashcraft K. An IL-6 link between obesity and cancer. Front Biosci. 2013; 5: 461–78.
24. Sarvas JL, Khafer N, Lees SJ. The IL-6 parado: context dependent interplay of SOCS3 and AMPK. J Diabetes Metab. 2013. doi: 10.4122/2155-6156.S13-003.
25. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8: 197–209.
26. McIntiernan A, Rajan KB, Tworoger SS, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003; 21: 1961–6.
27. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann NY Acad Sci. 2012; 1271: 37–43.
28. Grunt TW, Marianl GL. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 2013; 13: 188–204.
29. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011; 12: 1063–70.
30. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630–7.
31. Crujeiras AB, Diaz-Lagares A, Carreira MC, et al. Oxidative stress associated to dysfunctional adipose tissue: a potential link between obesity, type 2 diabetes mellitus and breast cancer. Free Radic Res. 2013; 47: 243–56.
32. Loft S, Olsen A, Moller P, et al. Association between 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion and risk of postmenopausal breast cancer: nested case-control study. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1289–96.
33. Dai Q, Gao YT, Shu XO, et al. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women’s Health Study. J Clin Oncol. 2009; 27: 2482–8.
34. Maccio A, Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. TheScientificWorldJournal. 2011; 11: 2020–36.
35. Basu S, Nachat-Kappes R, Caldeira-Chézet F, et al. Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal. 2013; 18: 323–60.
36. Cavailleri E, Frenkel K, Liehr JG, et al. Estrogens as endogenous genotoxic agents–DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000; 27: 75–93.
37. Mobile JA, Brueggemeier RW. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis. 2004; 25: 3–9.
38. Sasire-Serra J, Valle A, Company MM, et al. Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med. 2010; 48: 506–12.
39. Eswordly RS, Baker MA, Chu FF. Expression of selenium-dependent glutathione peroxidase in human breast tumor cell lines. Cancer Res. 1995; 55: 957–62.
40. Dalíe SH, Nicolau M, Sayeed A, et al. Oxidative stress pathways highlighted in
tumor cell immortalization: association with breast cancer outcome. Oncogene. 2007; 26: 6269–79.

41. Liang X, Lu B, Scott GK, et al. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol. 1998; 146: 151–61.

42. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000; 92: 1926–34.

43. Karlsson E, Pérez-Tenorio G, Amin R, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 2013; 15: R96.

44. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012; 30: 2844–52.

45. Zhang X, Smith-Warner SA, Collins LC, et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012; 30: 3468–77.

46. Singh B, Bhat HK. Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer. Carcinogenesis. 2012; 33: 2601–10.